| Similar Articles |
|---|
 |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.   |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Chemistry World
February 25, 2014
Sarah Houlton |
Megamerger brings Actavis into R&D race Generic drug giant Actavis is to buy speciality pharmaceutical firm Forest Labs in a deal worth about $25 billion, bringing Actavis into the drug discovery business. |
Chemistry World
June 24, 2015
Matthew Gunther |
Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal. |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Barr Labs and Pliva: Round 2 The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs win this battle yet. Investors, take note. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
Chemistry World
July 3, 2015
Phillip Broadwith |
Job cuts at Allergan and Transgene Biotech firms Allergan and Transgene are both shuttering manufacturing facilities and laying off hundreds of staff. |
Chemistry World
July 30, 2013
Emma Stoye |
Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
Chemistry World
November 27, 2015
Anthony King |
Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes. |
Pharmaceutical Executive
June 9, 2014
Cliff Kalb |
The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard. |
Chemistry World
October 28, 2015
Phillip Broadwith |
Job cuts at Daiichi, Perrigo and Cabot Three pharma firms -- Daiichi Sankyo, Perrigo and Allergan -- and specialty chemicals company Cabot are to cut thousands of jobs between them in restructuring efforts. |
Chemistry World
October 8, 2014
Phillip Broadwith |
Actavis boosts antibiotics with Durata buyout Pharma major Actavis has agreed to buy antibacterials specialist Durata Therapeutics for $675 million. |
The Motley Fool
September 19, 2006
Brian Lawler |
Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr. |
The Motley Fool
March 12, 2009
Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another. |
Chemistry World
December 21, 2015
Phillip Broadwith |
Is bigger really better? Something that's often glossed over in the aftermath of a pharmaceutical mega-merger is whether savings actually materialize, and at what cost to the future success of the businesses. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
Pharmaceutical Executive
November 1, 2005
Sara Calabro |
Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
The Motley Fool
December 17, 2011
Matt Koppenheffer |
This Week's Top Stock Gainers It wasn't a great week for the market, but some stocks and sectors were able to come out of it ahead of the rest. |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
The Motley Fool
July 18, 2007
Sham Gad |
Ackman Takes Aim at Target The activist investor from Pershing Square Capital Management looks to squeeze some more value out of the retailer's shares. |
